Citations

Clear

8 citation(s) found for "Serafim, L Piccolo".

C44-22 Unmasking the Leads: Pacemaker-induced Superior Vena Cava Syndrome Presenting as Bilateral Pleural Effusions
Serafim, L Piccolo, Anderson, D K

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.3512 Get It

Abstract Introduction Superior vena cava (SVC) syndrome results from the obstruction or occlusion of the SVC, leading to a range of complications depending on severity, location, and chronicity with the development of collateral circulation. We present a case of a patient with prior facial edema and subsequent development of bilateral pleural effusions whose evaluation led to discovery of SVC stenosis and occlusion of bilateral brachiocephalic veins, likely related to chronic indwelling pacemaker leads. Case Report A 73-year-old woman with bileaflet mitral valve prolapse with mild-to-moderate regurgitation, sinus node dysfunction status post pacemaker placement in 2014, atrial fibrillation and an unprovoked extensive right upper extremity deep venous thrombosis (DVT) managed on chronic apixaban therapy presented to clinic for evaluation of bilateral pleural effusions. One year prior to presentation, she developed facial and supraclavicular edema with positional dyspnea. A CT head and neck did not explain her abrupt facial edema though showed a left-sided pleural effusion, which was addressed locally with serial thoracenteses followed by tunneled pleural catheter placement. This ultimately led to discomfort without improvement in dyspnea, prompting catheter removal. She later developed a right-sided pleural effusion and underwent thoracentesis with the fluid analysis shown in Table 1. Physical exam was notable for collateral vessels along the chest wall and abdomen. The collateral vessels, unexplained pleural effusions, prior extensive right upper extremity DVT, and history of now resolved facial edema prompted CT venogram; this revealed occlusion of the right and left brachiocephalic veins and severe narrowing of the SVC with venous collaterals noted. PET-CT showed no evidence of malignancy. Electrophysiology consultation attributed the SVC stenosis to the indwelling pacemaker leads. The patient underwent SVC cavogram with successful angioplasty across right internal jugular vein down to the SVC with improvement in pressure gradient. After recanalization, there was no significant reaccumulation of pleural effusions on follow up and patient’s dyspnea improved. Discussion Pleural effusions in the setting of SVC syndrome have been described, most commonly due to thrombosis, device-related complications, or malignancy. This case highlights the importance of considering device-related vascular complications in patients with unexplained pleural effusions, particularly those with a history of intrathoracic devices or procedures. Management should target the underlying cause of the effusion; however long-term data on outcomes and optimal management strategies for pacemaker-related SVC syndrome remain limited. This abstract is funded by: None
Tragic Transformations and Differentiation Syndrome
Serafim, L. Piccolo, Moraes, Alice Gallo de

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3969-A3969

10.1164/ajrccm.2025.211.abstracts.a3969 Get It

Abstract Introduction: Differentiation syndrome (DS) is a life-threatening adverse drug reaction caused by differentiating agents, including all-trans retinoic acid, arsenic trioxide, inhibitors of mutant isocitrate dehydrogenase (e.g., enasidenib), and the FLT3 inhibitor gilteritinib. The proliferation of differentiated leukemic cells can alter cytokine balance, leading to tissue inflammation, but the pathogenesis remains incompletely understood. We present a case of severe DS in a patient with AML and multi-organ failure. Case: An 80-year-old female with a history of polycythemia vera and newly diagnosed AML, on decitabine, venetoclax, and enasidenib. She was admitted after her first treatment cycle with weakness, altered mental status, and neutropenic fever. Enasidenib was discontinued due to suspected DS, and she was treated with dexamethasone for five days. Three days after discontinuing steroids, her respiratory and mental status deteriorated, leading to a rapid response call and transfer to the ICU for acute hypoxemic respiratory failure. Point of care ultrasound revealed underfilled ventricles and collapsible IVC on inhalation. She became hypotensive and unresponsive, requiring intubation. Initial P/F was 72. PV tool with recruitment showed no low inflexion point but recruitable lung. Laboratory results revealed a WBC of 68.7 x 10⁹/L with 89% blasts which was increased from prior days and acute liver injury with hyperbilirubinemia. A CT scan revealed bilateral consolidations and pleural effusions with interlobular septal thickening. Despite initial oxygenation improvement with prone positioning, she remained hypotensive requiring norepinephrine, vasopressin, angiotensin II, and hydrocortisone. Methylene blue was administered with a favorable response. Leukocytosis worsened, and decitabine and hydroxyurea were initiated due to concern for uncontrolled acute leukemia. She was started on continuous renal replacement therapy (CRRT) for oliguric renal failure. After the fourth dose of decitabine, her shock resolved, urinary output improved, and leukocytosis decreased. However, in the following days, her oxygen requirements escalated, WBC again increased to 120 x 10⁹/L with 80% blasts, and she became hypotensive with signs of myocardial ischemia. She was ultimately transitioned to comfort care. Discussion: This case highlights severe DS following enasidenib administration, which progressed to multi-organ failure. Prompt initiation of systemic glucocorticoids is critical in the management of DS, and this condition should be considered in patients receiving active treatment for acute leukemia who require ICU-level care. Risk factors for DS development and the role of prophylaxis remain areas requiring further research in the context of acute leukemia treatment.
DERIVATION OF A MORTALITY PREDICTION MODEL IN CRITICAL CARE PATIENTS WITH CIRRHOSIS AND SEPSIS
Serafim, Laura Piccolo, Choi, Dae Hee , Weister, Timothy J. , Hanson, Andrew C. , Kamath, Patrick S. , Gajic, Ognjen, Simonetto, Douglas A. , Gajic, Ognjen , Moraes, Alice Gallo de

Mayo Clinic

Shock | March 22, 2024 | Volume: 61 | Issue: 3 | Pages: 382-386

10.1097/shk.0000000000002323 | PMID 38517233 Get It

ABSTRACT Objective: The aim of the study is to develop a predictive model for in-hospital mortality in critically ill patients with cirrhosis and sepsis, using clinical and laboratory data. Design: This is a retrospective cohort study. Setting: Medical and mixed intensive care units (ICUs) of a tertiary medical center. Patients: Cirrhotic adults were admitted with sepsis to the ICUs from January of 2007 to May of 2017. Interventions: None. Measurements and Main Results: Of 2,595 ICU admissions of patients with cirrhosis, 277 with first ICU admission for sepsis were included in the analysis, and 37% died in the hospital. Patients who stayed in the ICU for at least 6 h (n = 275) were considered for the multivariate model. Ten-fold cross-validation was used to estimate best parameter values and model performance, and the final model was chosen as the model maximizing area under the receiver-operating characteristic curve. Variables in order of impact were Acute Physiology and Chronic Health Evaluation (APACHE) III score, initial serum lactate, conjugated bilirubin, serum creatinine, model for end-stage liver disease score, age, body mass index, and serum hemoglobin. The final best model from cross-validation presented an area under the receiver operator characteristic curve (AUC) of 0.75, using a cut-point of 50% estimated probability, sensitivity and specificity were 0.46 and 0.90, respectively, with positive predictive value of 0.72 and negative predictive value of 0.74. These results were similar to the APACHE III only model (AUC = 0.74, sensitivity = 0.43, specificity = 0.89, positive predictive value = 0.69, negative predictive value = 0.73). Conclusion: The combination of initial serum lactate level, conjugated bilirubin, initial serum creatinine, model for end-stage liver disease score, age, body mass index, and serum hemoglobin did not yield meaningful improvement in the AUC and did not provide advantage over the APACHE III score for the prediction of in-hospital mortality in critically ill patients with cirrhosis and sepsis.
Serum lactate and mean arterial pressure thresholds in patients with cirrhosis and septic shock
Smith, Thomas N. , Choi, Chansong , Rattan, Puru , Serafim, Laura Piccolo, Kassmeyer, Blake A., Lennon, Ryan J. , Gajic, Ognjen , Olson, Jody C. , Kamath, Patrick S. , Moraes, Alice Gallo de , Piccolo Serafim, Laura, Simonetto, Douglas A , Choi, Chansong , Gallo de Moraes, Alice , Gajic, Ognjen , Simonetto, Douglas A.

Mayo Clinic

Hepatology Communications | January 5, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1097/hc9.0000000000000353 | PMID 38180993 Get It

Background: The Sepsis-3 guidelines have incorporated serum lactate levels of >2 mmol/L in septic shock definition to account for higher observed mortality. Further evidence is needed to support this threshold in cirrhosis, as well as target mean arterial pressure (MAP) during resuscitation. Methods: This observational cohort study investigated the association between initial serum lactate and resuscitation MAP levels on in-hospital mortality in patients with and without cirrhosis. Patients admitted to the intensive care unit for the treatment of septic shock between 2006 and 2021 in a quaternary academic center were included. Patients with cirrhosis documented on imaging and International Classification of Disease codes (n=595) were compared to patients without cirrhosis (n=575). The association of intensive care unit admission lactate levels and median 2-hour MAP with in-hospital mortality and the need for continuous renal replacement therapy was assessed. The association between median 24-hour MAP and in-hospital mortality was analyzed post hoc. Results: Within the cirrhosis group, admission lactate levels of 2–4 and >4 mmol/L were associated with increased in-hospital mortality compared to lactate <2 mmol/L [adjusted odds ratio (aOR): 1.69, CI: 1.03–2.81, aOR: 4.02, CI: 2.53–6.52]. Median 24-hour MAP 60–65 and <60 mm Hg were also associated with increased in-hospital mortality compared with MAP >65 mm Hg (aOR: 2.84, CI: 1.64–4.92 and aOR: 7.34, CI: 3.17–18.76). In the noncirrhosis group, associations with in-hospital mortality were weaker for lactate 2–4 and >4 mmol/L (aOR: 1.32, CI: 0.77–2.27 and aOR: 2.25, CI: 1.40–3.67) and median 24-hour MAP 60–65 and <60 mm Hg (aOR: 1.70, CI: 0.65–4.14 and aOR: 4.41, CI: 0.79–29.38). Conclusions: These findings support utilizing lactate >2 mmol/L in the definition of septic shock, as well as a target MAP of >65 mm Hg during resuscitation in patients with cirrhosis.
Relationship Between Body Mass Index and Survival Among Critically Ill Patients With Cirrhosis
Choi, Chansong , Lennon, Ryan J , Choi, Dae Hee, Serafim, Laura Piccolo, Allen, Alina M, Kamath, Patrick S, Shah, Vijay H, Moraes, Alice Gallo de, Simonetto, Douglas A, Simonetto, Douglas A. , Choi, Chansong , De Moraes, Alice Gallo, Simonetto, Douglas A , Choi, Chansong, Lennon, Ryan J, Choi, Dae Hee, Serafim, Laura Piccolo, Allen, Alina M, Kamath, Patrick S, Shah, Vijay H, Moraes, Alice Gallo de, Simonetto, Douglas A

Mayo Clinic

Journal of Intensive Care Medicine | July 5, 2021 | Volume: 37 | Issue: 6 | Pages: 817-824

10.1177/08850666211029827 | PMID 34219539 Get It

Background: Obesity paradox is a phenomenon in which obesity increases the risk of obesity-related chronic diseases but paradoxically is associated with improved survival among obese patients with these diagnoses. Objectives: The aim of this study was to explore the obesity paradox among critically ill patients with cirrhosis admitted to the Intensive Care Unit. Methods: A retrospective cohort of 1,143 consecutive patients with cirrhosis admitted to the ICU between January of 2006 and December of 2015 was analyzed. Primary outcome of interest was in-hospital mortality with secondary end points including ICU and short-term mortality at 30 days post ICU admission. Results: Logistic regression with generalized additive models was used, controlling for clinically relevant and statistically significant factors to determine the adjusted relationship between body mass index (BMI) and ICU, post-ICU in-hospital, and 30 day mortality following ICU discharge. ICU and hospital length of stay was similar across all BMI classes. Adjusted ICU mortality was also similar when stratified by BMI. However, a significant reduction in post-ICU hospital mortality was observed in class I and II obese patients with cirrhosis (BMI 30-39.9 kg/m 2 ) compared to normal BMI (OR = 0.41; 95% CI, 0.20 to 0.83; P = 0.014). Similarly, overweight (BMI 25-29.9 kg/m 2 ) and class I and II obese patients with cirrhosis had significantly lower 30-day mortality following ICU discharge (OR = 0.52, 95% CI 0.31 to 0.87; P = 0.014; OR = 0.50, 95% CI 0.29 to 0.86; P = 0.012, respectively) compared to those with normal BMI. Conclusion: The signal of obesity paradox is suggested among critically ill patients with cirrhosis.
Clinical Effect of Systemic Steroids in Patients with Cirrhosis and Septic Shock
Serafim, Laura Piccolo, Simonetto, Douglas A., Anderson, Alexandra L., Choi, Dae Hee, Weister, Timothy J., Hanson, Andrew C., Kamath, Patrick S., Gajic, Ognjen, Moraes, Alice Gallo de, Simonetto, Douglas A. , Piccolo Serafim, Laura, Simonetto, Douglas A , Serafim, Laura Piccolo, Anderson, Alexandra L., Choi, Dae Hee, Weister, Timothy J., Hanson, Andrew C., Kamath, Patrick S., Gajic, Ognjen, Moraes, Alice Gallo de

Mayo Clinic

Shock | June 16, 2021 | Volume: 56 | Issue: 6 | Pages: 916-920

10.1097/shk.0000000000001822 | PMID 34132218 Get It

ABSTRACT Purpose: Evidence regarding the utility of systemic steroids in treating patients with cirrhosis and septic shock remains equivocal. This study aimed to evaluate and elucidate the association of steroid use with outcomes and adverse effects in a cohort of patients with cirrhosis and septic shock. Patients and methods: Retrospective cohort study of patients with cirrhosis and septic shock admitted to a tertiary hospital intensive care unit (ICU) from January 2007 to May 2017, using a validated ICU Datamart. Patients who received vasopressors within 6 h of ICU admission were included in the multivariate analysis. The effect of steroids on outcomes was evaluated using multivariable regression, adjusting for confounding variables. Results: Out of 179 admissions of patients with cirrhosis and septic shock, 56 received steroids during the ICU admission. Patients who received steroids received a higher total dose of vasopressors (91.2 mg vs. 39.1 mg, P = 0.04) and had a lower initial lactate level (1.8 mmol/L vs. 2.6 mmol/L, P = 0.007). The multivariate analysis included 117 patients and showed no significant differences in mortality, length of ICU admission, or length of hospital stay. Bleeding events, delirium, and renal-replacement therapy requirements were also not associated with the use of steroids. Conclusion: The use of systemic steroids was more prevalent in cirrhotic patients with higher vasopressor requirements. It was not associated with decreased mortality or increased ICU- and hospital-free days, or to adverse effects.
A systematic review of adherence to physical activity interventions in individuals with type 2 diabetes
MacDonald, Christopher , Ried‐Larsen, Mathias , Soleimani, Jalal , Alsawas, Mouaz , Ismail, Abdalla, Serafim, Laura Piccolo, Yang, Ting , Prokop, Larry, Joyner, Michael J. , Barwise, Amelia , MacDonald, Christopher S , Joyner, Michael, Murad, Mohammad Hassan, Barwise, Amelia K , Joyner, Michael J , Alsawas, Mouaz , Lieberman, Daniel E. , Murad, M. Hassan

Mayo Clinic

Diabetes/Metabolism Research and Reviews | March 9, 2021 | Volume: 37 | Issue: 8 | Pages: No page available

10.1002/dmrr.3444 | PMID 33769660 Get It

Abstract Lifestyle interventions are pivotal for successful management of type 2 diabetes (T2D), however, the proportion of people with T2D adhering to physical activity advice has not been thoroughly studied. The purpose of this systematic review was to summarise the evidence on adherence to exercise or physical activity components in lifestyle interventions in those with T2D. We searched MEDLINE EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and Scopus on 12 November 2019. Eligible studies enrolled adults with T2D and reported the proportion of adherence to lifestyle interventions as a primary or secondary outcome. We included 11 studies (nine randomised controlled trials (RCTs) enrolling 1717 patients and two nonrandomised studies enrolling 62 patients). Only one of the studies had low risk of bias. The proportion of participants adhering to physical activity varied from 32% to 100% with a median of 58%. Adherence was higher in interventions using supervised training and lowest in interventions using remote coaching and the adherence rate in observational studies was higher compared to RCTs (92% vs. 55%; p < 0.01). Study duration, risk of bias, or participants' sex, were not associated with adherence to physical activity. The proportion of those with T2D adhering to physical activity interventions for T2D varies widely and most of the included studies had a high risk of bias. These findings have important implications for planning and power analysis of future trials and when counselling patients about lifestyle interventions including physical activity or exercise components.
Management of Sepsis in Patients With Cirrhosis: Current Evidence and Practical Approach
Simonetto, Douglas A. , Serafim, Laura Piccolo, Moraes, Alice Gallo de , Gajić, Ognjen, Kamath, Patrick S. , Piccolo Serafim, Laura, Gallo de Moraes, Alice , Simonetto, Douglas A , Gajic, Ognjen

Mayo Clinic

Hepatology | December 5, 2018 | Volume: 70 | Issue: 1 | Pages: 418-428

10.1002/hep.30412 | PMID 30516866 Get It

Sepsis in patients with cirrhosis is associated with high mortality. An impaired immune response accounts for the increased infection risk observed in these patients. Hemodynamic and systemic changes suggestive of sepsis may be observed in patients with cirrhosis in the absence of infection; therefore, diagnosis and treatment of sepsis may be delayed. The optimal management of the critically ill patient with sepsis and cirrhosis has not been well established and is generally extrapolated from consensus guidelines and expert recommendations made for management of patients without cirrhosis with sepsis. Despite the lack of strong evidence, we propose a contemporary pragmatic approach to sepsis management in patients with cirrhosis, including the choice of fluids, vasopressors, and antibiotics.